|
News Briefs Maryland: Institute of Human Virology Plans Clinical Trial of AIDS VaccineMarch 14, 2002 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! The Institute for Human Virology, a center of the University of Maryland Biotechnology Institute, plans to begin clinical trial of an AIDS vaccine developed by Aventis Co. of France, the first such human test of the treatment in the United States. The vaccine is made from an inactivated HIV protein called Tat that is normally key to the replication of the AIDS virus. The inactive form of the protein, known as Tat toxoid, is designed to stimulate the production of antibodies to the real protein, thereby thwarting HIV with a vigorous immune response. Wall Street Journal 03.14.02; David Hamilton A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
|